Acar Emine, Bekiş Recep, Polack Berna
Department of Nuclear Medicine, School of Medicine, Dokuz Eylul University, Izmir, Turkey.
Curr Med Imaging Rev. 2019;15(6):589-594. doi: 10.2174/1573405615666190225155254.
The aim of this study was to compare images from Tc-99m MDP bone scan (BS) and Ga-68 PSMA PET/CT of patients with prostate cancer in terms of bone metastases.
Overall, 34 patients exhibited a mean age of 66 ± 9.5 (50-88) years, mean PSA of 51 ± 159ng/ml (0-912), and mean Gleason score of 8 (6-9). BS and Ga-68 PSMA PET/CT were applied to 34 patients within 30 days, and the results were evaluated, retrospectively. In both tests, radiopharmaceutical uptake in bones were compared.
In 7 patients (20.5%), uptake was not significant on BS and Ga-68 PSMA PET / CT images, which is related to metastasis. In 14 (41%) patients, bone metastases were observed in both examinations. However, more metastatic lesions were observed in the Ga-68 PSMA PET/CT of 3 patients and in the bone scintigraphy of 2 patients. PSMA expression was not observed on Ga-68 PSMA PET / CT in 13 (38%) patients with increased activity in bone scintigraphy. Two (6%) of these patients were thought to be metastatic, 2 (6%) were suspicious for metastasis, and 9 (26%) had no metastasis. When a lesion-based evaluation was performed, a total of 480 activities were evaluated: increased activity uptake was found in 305 BS, and 427 PSMA expression activity was detected. Furthermore, 435 of these activities were evaluated as metastatic.
Ga-68 PSMA PET/CT provides an additional contribution to the BS evaluation of activity areas because of the presence of PSMA expression and anatomical lesions. In 6% of the patients, activity on BS and metastatic appearance in CT images were observed and the presence of lesions in the absence of PSMA was determined. This suggests that bone metastases without PSMA expression may also be present.
本研究旨在比较前列腺癌患者的锝-99m亚甲基二膦酸盐骨扫描(BS)和镓-68前列腺特异性膜抗原(PSMA)PET/CT在骨转移方面的图像。
总共34例患者,平均年龄66±9.5(50 - 88)岁,平均前列腺特异性抗原(PSA)为51±159ng/ml(0 - 912),平均 Gleason评分8(6 - 9)。在30天内对34例患者进行了BS和镓-68 PSMA PET/CT检查,并对结果进行回顾性评估。在两项检查中,均比较了骨骼中的放射性药物摄取情况。
7例(20.5%)患者在BS和镓-68 PSMA PET/CT图像上摄取不明显,这与转移有关。14例(41%)患者在两项检查中均观察到骨转移。然而,在3例患者的镓-68 PSMA PET/CT和2例患者的骨闪烁显像中观察到更多的转移病灶。在骨闪烁显像活性增加的13例(38%)患者中,镓-68 PSMA PET/CT上未观察到PSMA表达。这些患者中有2例(6%)被认为是转移性的,2例(6%)怀疑有转移,9例(26%)无转移。当进行基于病灶的评估时,共评估了480个活性区域:在305个BS中发现活性摄取增加,检测到427个PSMA表达活性。此外,这些活性区域中有435个被评估为转移性。
由于PSMA表达和解剖学病变的存在,镓-68 PSMA PET/CT为BS对活性区域的评估提供了额外的帮助。6%的患者在BS上有活性而CT图像上有转移表现,且确定了无PSMA时病变的存在。这表明可能也存在无PSMA表达的骨转移。